As of Nov 19, 2026, 0 of 2 active firms rate FMS a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
FMS EPS & revenue forecast
EPS · NEXT QUARTER
$0.43
Range $0.43 – $0.43 · 1 analysts · -5% YoY
Next period, 1 analysts expect Fresenius Medical Care Corporation to earn $0.43 a share (range $0.43 – $0.43), versus $0.46 a year earlier. Full-year consensus is $2.47, growing to $2.34 the year after.
REVENUE · NEXT QUARTER
$4.7B
Range $4.7B – $4.8B · 1 analysts · +3% YoY
Revenue is expected to reach $4.7B (range $4.7B – $4.8B), +2.5% year-over-year. Full-year consensus is $19.5B, rising to $20.1B next year.
Top analysts covering Fresenius Medical Care Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FMS.
#1
DM
David Macdonald
Truist Securities · Rank #111
Neutral
$24.00+14.6% to target
Overall win rate
50%
+ Follow
#2
SL
Susannah Ludwig
Bernstein
Neutral
$25.80+23.2% to target
Coverage
—
+ Follow
#3
LC
Lisa Clive
Bernstein
Neutral
$25.80+23.2% to target
Coverage
—
+ Follow
#4
MB
Marianne Bulot
Bank of America Securities
Sell
$22.00+5.1% to target
Coverage
—
+ Follow
#5
GD
Graham Doyle
UBS
Sell
No targeton FMS
Coverage
—
+ Follow
FMS stock forecast FAQ
What is FMS's average 12-month price target?+
The 2 active firms with a live target average $24.90 for Fresenius Medical Care Corporation over the next 12 months, ranging from a $25.80 high to a $24.00 low, as of Nov 19, 2026.
Is FMS stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for FMS?+
The Street-high target is $25.80 (Bernstein), and the Street-low is $24.00 (Truist Securities). The average of all 2 active-firm targets is $24.90.
How many active Wall Street firms cover FMS?+
2 active firms have a recognized rating on Fresenius Medical Care Corporation as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering FMS?+
Among analysts who currently cover FMS, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #111). Their current call is Neutral with a $24.00 target.
What is Fresenius Medical Care Corporation's projected EPS for next quarter?+
The consensus estimate is $0.43 per share (range $0.43 – $0.43) across 1 analysts. Full-year EPS is projected at $2.47, rising to $2.34 the following year.
How much revenue is Fresenius Medical Care Corporation expected to report next quarter?+
Consensus revenue is $4.7B (range $4.7B – $4.8B). Full-year revenue is projected at $19.5B, growing to $20.1B next year.
Have analysts been upgrading or downgrading FMS lately?+
As of Nov 19, 2026, 0 of 2 active firms rate FMS a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FMS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.